Search

OBEJECTIVE: To probe into the efficacy of gliquidone combined with atorvastatin in treatment of early diabetic kidney disease(DKD). METHODS: 64 patients with early DKD were selected and divided into control group and observation group via random number table, with 32 cases in each. The control group was given 45-120 mg/d of gliquidone orally, while the observation group was given 10 mg/d of atorvastatin orally based on the control group,levels of serum creatinine(SCr),urinary albumin excretion rate in 24 h(24 h UAER),glycosylated hemoglobin(HbA1c),total cholesterol(TC) and low density lipoprotein cholesterin(LDL-C) of two groups were compared. RESULTS: After 3-month treatment,the HbA1c and 24 h UAER levels of both groups had been significantly decreased, with statistically significant differences(P<0.05); the 24 h UAER,TC and LDL-C levels of observation group were significantly lower than those of the control group, with statistically significant differences(P<0.05). After 6-month treatment,the HbA1c and 24 h UAER levels of both groups had been significantly decreased, with statistically significant differences(P<0.05); the Scr level of observation group was significantly lower than that of before treatment, with statistically significant differences(P<0.05), while there was no statistical significance in difference of SCr level in control group between before and after treatment(P<0.05); at 6 months after treatment,the 24 h UAER,SCr,TC and LDL-C levels of observation group were significantly lower than those of 3 months after treatment, and also significantly lower than those of the control group, with statistically significant differences(P<0.05). CONCLUSIONS: The combination of gliquidone and atorvastatin is more beneficial to the improvement of early DKD, which makes more significant differences in long-term blood lipid control and kidney protection. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the short-term economic effects of 3 kinds of sulfonylurea drugs in the initial treatment of type II diabetes. METHODS: 180 patients with type II diabetes admitted into Hongqi Hospital of Mudanjiang Medical University from Aug. 2012 to Aug. 2015 were selected to be divided into glimepiride group, gliquidone group and glipizide group via the random number table, with 60 cases in each. Patients in glimepiride group were treated with glimepiride 4 mg, once a day; the gliquidone group were given gliquidone 15 mg, 3 times a day; and the glipizide group received glenn pyrazine 15 mg, once a day; 12 weeks for a treatment course. And the blood glucose, HbA1c were determined during the treatment process. RESULTS: The total effective rate of glimepiride group was was significantly higher than that of glipizide group; the decent percentage of blood glucose after 2 h and HbA1c of glimepiride group were significantly higher than those of gliquidone group and glipizide group , with statistically significant difference (P <0.05) .To set the indicators as decent percentage of 2 h postprandial blood glucose , compared with glipizide group, glimepiride group, gliquidone group had increased by 8.44 yuan, 17.54 yuan. And to set the indicators as decent percentage of HbA1c, compared with glipizide group , glimepiride group , gliquidone group had increased by 36.49 yuan, 53.96 yuan. The decent percentage of 2 h postprandial blood glucose and HbA1c were insensitive to the price of drugs; the differences of incidence of adverse drug reactions among three groups were not significant (P>0.05). CONCLUSIONS: The short-term economics effects of glimepiride is better than gliquidone and glipizide in the initial treatment of type 2 diabetes. [ABSTRACT FROM AUTHOR]